AstraZeneca (AZN)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 9.87 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 2.87 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Dec | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | TTM | 2013E | 2014E | CAGR / Avg | |
| Revenue | $m | ||||||||||
| Operating Profit | $m | ||||||||||
| Net Profit | $m | ||||||||||
| EPS Reported | $ | ||||||||||
| EPS Normalised | $ | ||||||||||
| EPS Growth | % | ||||||||||
| PE Ratio | x | ||||||||||
| PEG | x | ||||||||||
| Profitability | |||||||||||
| Operating Margin | % | ||||||||||
| ROA | % | ||||||||||
| ROCE | % | ||||||||||
| ROE | % | ||||||||||
| Cashflow | |||||||||||
| Op. Cashflow ps | $ | ||||||||||
| Capex ps | $ | ||||||||||
| Free Cashflow ps | $ | ||||||||||
| Last ex-div: 13th Feb, paid: 18th Mar more... Dividends | |||||||||||
| Dividend ps | $ | ||||||||||
| Dividend Growth | % | ||||||||||
| Dividend Yield | % | ||||||||||
| Dividend Cover | x | ||||||||||
| Balance Sheet | |||||||||||
| Cash etc | $m | ||||||||||
| Working Capital | $m | ||||||||||
| Net Fixed Assets | $m | ||||||||||
| Net Debt | $m | ||||||||||
| Book Value | $m | ||||||||||
| Average Shares | m | ||||||||||
| Book Value ps | $ | +13.4% | |||||||||
FINANCIAL BRIEF: For the three months ended 31 March 2013, AstraZeneca plc revenues decreased 13% to $6.39B. Net income decreased 38% to $1.01B. Revenues reflect United States segment decrease of 16% to $2.45B, Western Europe segment decrease of 15% to $1.66B. Net income also reflects Other Operating decrease of 48% to $132M (income), Restructuring Cost - Selling/General/Adm increase of 19% to $240M (expense). more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Mar '13) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 1 | 4 | 18 | 4 | 2 |
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca’s products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. In August 2012, Alliance Pharma plc’s subsidiary, Alliance Pharmaceuticals Limited, acquired the antimalarial brands. In August 2012, the Company announced the acquisition of Amylin Pharmaceuticals, Inc. by Bristol-Myers Squibb Company.
Directors: Pascal Soriot (CEO) 53, Simon Lowth (CFO) 51, Lynn Tetrault (Exec. VP) , Ruud Dobber (Exec. VP) , Marc Dunoyer (Exec. VP) , Paul Hudson (Exec. VP) , Bahija Jallal (Exec. VP) , Mark Mallon (Exec. VP) , Briggs Morrison (Exec. VP) , Menelas Pangalos (Exec. VP) ,
No. of Employees: 51,700 No. of Shareholders: 111,111
| Last Annual | December 31st, 2012 |
| Last Interim | March 31st, 2013 |
| Shares in Issue | 1,248,156,115 |
| Free Float | 1.25bn (99.9%) |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | E300 PHAR & BIO IDX, FTSE Eurofirst 100 , FTSEUROFIRST 300 , E300 ex EURO COR, FTSE Higher Yield , FTSE 350 Act , FTSE Global 100, FT350 Phar & Bio , FTSE 100 , FTSE 100 Eod Gbp , FTSE Techmark All-share, |
| Exchange |
London Stock Exchange (Full) |
| Eligible for | an ISA? a SIPP? |
| Address | 2 Kingdom Street Paddington, LONDON, W2 6BD, United Kingdom |
| Web | http://www.astrazeneca.com/ |
| Phone | +44 20 76048000 |
| Contact | James Ward-Lilley (IR Contact Officer) |
| Registrar | Equiniti Limited |
| Auditors | KPMG Audit PLC |
| Tue 2:00pm | Director/PDMR Shareholding |
| 8th May | Director/PDMR Shareholding |
| 8th May | Director/PDMR Shareholding |
| 2nd May | Director/PDMR Shareholding |
| 1st May | Director/PDMR Shareholding |
| 1st May | Total Voting Rights |
Recent ↓
